TD Cowen Reiterates Buy Rating on Protara Therapeutics (TARA): "encouraged by Q4 operational update"
Tweet Send to a Friend
TD Cowen analyst Stacy Ku reiterated a Buy rating and $30.00 price target on Protara Therapeutics (NASDAQ: TARA)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
